Recovering scientist turned early stage VC A biotech optimist fighting gravity

Hotspot Therapeutics Turns Up The Heat On Natural Allostery
July 17, 2018

Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an enzymatic activity associated with a disease. These drugs bind and compete against the natural substrate of the protein at what

Leave a comment

A Hat Trick Of Cell And Gene Therapy IPOs: Avro, Magenta, and Unum
June 28, 2018

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

Leave a comment

Float Like A Butterfly: Agility In Biotech
June 13, 2018

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around

Leave a comment

Farewell to Zafgen: A Personal Reflection On Board Evolution
June 7, 2018

Today, Zafgen announced my resignation from their Board of Directors after 12 years of service. It’s a bittersweet moment for me: having been there since the beginning, I’ve watched, and supported, the Zafgen story through all the ups and downs

Leave a comment

Biotech CEO Pay: Inflation Held At Bay
June 1, 2018

The private biotech sector is awash in capital today: funding over the last few quarters has been record-breaking, up over 250% since 2013, as biotech CEOs have worked hard to strengthen their companies’ balance sheets.  But in the process of

Leave a comment

Trains, Bicycles, And Business Development
May 30, 2018

This blog post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. It’s heresy to write this but it’s trains not bicycles that come to mind when describing our partnering

Leave a comment

New Directions In Alzheimer’s Disease Research And Development
May 15, 2018

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Disappointing results in Alzheimer’s clinical trials seem to be announced on an almost monthly, and sometimes weekly basis: Merck’s

Leave a comment

Right From The Beginning: Returning To The Origins Of The Orphan Drug Movement
May 1, 2018

This blog was co-written by Doug Kerr, Head of Preclinical Research & Clinical Development, and Geoff McDonough, CEO, both of GenerationBio, as part of the From The Trenches feature of LifeSciVC. Our industry stands at the beginning of the most

Leave a comment

Another Trophy Quarter For VC-Backed Biotech Funding
April 30, 2018

The flood of capital continues to pour into the private biotech ecosystem, marking the current climate as the most prolific period of investing into the sector of all time. The first three months of 2018 secured yet another “biggest quarter

Leave a comment

Little by Little: Real Life Lessons In Business Development
April 16, 2018

This blog was written by Tariq Kassum, COO and Head of Corporate Development at Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Experience can be a tough teacher. Over the last two decades as a biotech

Leave a comment

Life After ECHO-301: Lessons Learned About Modulating IDO/TDO To Treat Cancer
April 12, 2018

This blog was written by Mark Manfredi, CEO of Kyn Therapeutics and former Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC.  Last week we learned about the failure of the much anticipated ECHO-301/KEYNOTE-252 trial that studied

Leave a comment

Caravans of Biotech Immigrant Executives
April 5, 2018

Recently there’s been talk of a caravan of immigrants marching towards the United States, principally focused on Mexico and Central America.  But there’s also another caravan, this one at work in the biopharma business: the long term migration of science

Leave a comment